@NP	Chondroitinase ABC -LRB- ChABC -RRB-	1045
@NP	Chondroitinase ABC	1045
@NP	ChABC	1065
@NP	a bacteria enzyme	1073
@NP	the glycosaminoglycan	1130
@NP	GAG	1153
@NP	side chain of CSPG to promote axonal regrowth across the injured site	1158
@NP	side chain	1158
@NP	CSPG	1172
@NP	axonal regrowth	1188
@NP	the injured site	1211
@NP	Our previous study	1229
@NP	long-term delivery	1263
@NP	ChABC -LRB- 1 U/ml , injection volume 0.6 µl for one animal -RRB-	1285
@NP	ChABC	1285
@NP	1 U/ml , injection volume 0.6 µl for one animal	1292
@NP	1 U/ml	1292
@NP	injection volume 0.6 µl for one animal	1300
@NP	injection volume	1300
@NP	0.6 µl for one animal	1317
@NP	0.6 µl	1317
@NP	one animal	1327
@NP	intrathecal catheter	1343
@NP	the inhibitory effect of limiting axonal re-growth after SCI	1379
@NP	the inhibitory effect	1379
@NP	axonal re-growth	1413
@NP	SCI	1436
@NP	The functional behavior	1441
@NP	following ChABC treatment	1491
@NP	Little axons re-grow	1518
@NP	the lesion site of the spinal cord but not enough	1546
@NP	the lesion site	1546
@NP	the spinal cord but not enough	1565
@NP	the spinal cord	1565
@NP	enough	1589
@NP	axon innervations	1607
@NP	targets	1628
@NP	this article	1640
@NP	we	1654
@NP	ChABC administration	1667
@NP	olfactory mucosa progenitor cell -LRB- OMPC -RRB-	1698
@NP	olfactory mucosa progenitor cell	1698
@NP	OMPC	1732
@NP	transplantation	1738
@NP	axonal re-growth	1766
@NP	the lesion site	1790
@NP	the consistency of stepping in spinally transected rats	1818
@NP	the consistency	1818
@NP	spinally transected rats	1849
@NP	These OMPCs	1875
@NP	NG2 + cell lineages after transplanting into the spinal cord parenchyma	1897
@NP	NG2 + cell lineages	1897
@NP	the spinal cord parenchyma	1941
@NP	OMPCs	1973
@NP	the lesion region of spinal cord	2019
@NP	the lesion region	2019
@NP	spinal cord	2040
@NP	the spatial and temporal characteristics of the step cycle in rats that	2063
@NP	the spatial and temporal characteristics	2063
@NP	the step cycle in rats that	2107
@NP	the step cycle	2107
@NP	rats that	2125
@NP	rats	2125
@NP	a complete spinal cord transaction	2143
@NP	continuousChABCsupply andOMPCtransplantation	2188
@NP	The gait characteristics of treated rats on a treadmill	2234
@NP	The gait characteristics	2234
@NP	treated rats on a treadmill	2262
@NP	treated rats	2262
@NP	a treadmill	2278
@NP	that of intact rats	2321
@NP	that	2321
@NP	intact rats	2329
@NP	future	2345
@NP	the mechanism of restoring the injured spinal cord	2353
@NP	the mechanism	2353
@NP	the injured spinal cord	2380
@NP	Fig. 1 .	2436
@NP	Fig.	2436
@NP	1	2441
@NP	-LRB- A -RRB-	2444
@NP	Morphology and cellular proliferation rates	2448
@NP	olfactory mucosa-derived progenitor cells , which were pre-induced by GDNF	2495
@NP	olfactory mucosa-derived progenitor cells	2495
@NP	GDNF	2564
@NP	-LRB- B -RRB- These OMPCs	2570
@NP	-LRB- B -RRB-	2570
@NP	These OMPCs	2574
@NP	a greater number	2596
@NP	neuritis	2626
@NP	red arrow	2636
@NP	GDNF-containing medium in culture	2673
@NP	GDNF-containing medium	2673
@NP	culture	2699
@NP	they	2712
@NP	the negative control method	2729
@NP	The OMPCs	2758
@NP	GDNF-induction for 7 days	2791
@NP	GDNF-induction	2791
@NP	7 days	2810
@NP	immunocytochemistry assay	2818
@NP	cellular determination	2857
@NP	various antibodies such as NG2 and O4	2885
@NP	various antibodies	2885
@NP	NG2 and O4	2912
@NP	7 days , -LRB- C -RRB-	2930
@NP	7 days	2930
@NP	C	2939
@NP	a large number of GDNF-induced OMPCs	2942
@NP	a large number	2942
@NP	GDNF-induced OMPCs	2960
@NP	NG2 -LRB- a marker of oligodendrocyte progenitor cells -RRB- and O4	2989
@NP	NG2	2989
@NP	a marker of oligodendrocyte progenitor cells	2994
@NP	a marker	2994
@NP	oligodendrocyte progenitor cells	3006
@NP	O4	3044
@NP	few NG2 + cells	3057
@NP	few NG2	3057
@NP	cells	3066
@NP	O4	3090
@NP	similar to GDNF-induced OMPCs , -LRB- D -RRB- the original OMPCs	3094
@NP	similar to GDNF-induced OMPCs , -LRB- D -RRB-	3094
@NP	similar to GDNF-induced OMPCs	3094
@NP	D	3126
@NP	the original OMPCs	3129
@NP	GFAP-free	3149
@NP	NG2	3179
@NP	fewer cells	3188
@NP	O4 -LRB- scale bar , 20µm -RRB-	3210
@NP	O4	3210
@NP	scale bar , 20µm	3214
@NP	scale bar	3214
@NP	20µm	3225
@NP	Fig. 2 .	3233
@NP	Fig.	3233
@NP	2	3238
@NP	-LRB- A -RRB- Photomicrographs of a longitudinal section of spinal cord	3241
@NP	-LRB- A -RRB- Photomicrographs	3241
@NP	A	3242
@NP	a longitudinal section of spinal cord	3265
@NP	a longitudinal section	3265
@NP	spinal cord	3291
@NP	8 weeks after treatment	3303
@NP	8 weeks	3303
@NP	treatment	3317
@NP	The white arrow	3328
@NP	the T8 transection site	3350
@NP	-LRB- B and C -RRB-	3375
@NP	B	3376
@NP	C	3382
@NP	Higher magnification images of regions outlined in -LRB- A -RRB-	3385
@NP	Higher magnification images	3385
@NP	regions outlined in -LRB- A -RRB-	3416
@NP	regions	3416
@NP	A	3437
@NP	Some BrdU-labeled OMPCs	3441
@NP	Some	3441
@NP	OMPCs	3459
@NP	NG2 + cells	3485
@NP	the rostral	3499
@NP	B , white arrow	3512
@NP	B	3512
@NP	white arrow	3515
@NP	caudal stumps	3532
@NP	C , white arrow	3547
@NP	C	3547
@NP	white arrow	3550
@NP	the spinal cord transected site	3566
@NP	Scale bar	3599
@NP	100µm	3612
@NP	-LRB- D -RRB- Less GFAP + cells	3619
@NP	-LRB- D -RRB- Less	3619
@NP	-LRB- D -RRB-	3619
@NP	GFAP + cells	3628
@NP	BrdU + cells near the spinal cord lesion regions	3656
@NP	BrdU + cells	3656
@NP	the spinal cord lesion regions	3673
@NP	OMPC transplantation	3710
@NP	-LRB- E and F -RRB-	3732
@NP	E	3733
@NP	F	3739
@NP	Higher magnification images from the regions in -LRB- D -RRB-	3742
@NP	Higher magnification images	3742
@NP	the regions in -LRB- D -RRB-	3775
@NP	the regions	3775
@NP	D	3791
@NP	BrdU + cells	3795
@NP	BrdU	3795
@NP	cells	3801
@NP	the spinal cord transection site	3824
@NP	these cells	3862
@NP	astrocytes	3901
@NP	GFAP -LRB- green -RRB-	3924
@NP	GFAP	3924
@NP	Sham control -LRB- injury alone without treatment group -RRB-	3938
@NP	Sham control	3938
@NP	injury alone without treatment group	3952
@NP	injury alone	3952
@NP	treatment group	3973
@NP	G	4004
@NP	no BrdU + cells	4012
@NP	no BrdU	4012
@NP	cells	4021
@NP	the injected region of spinal cord	4045
@NP	the injected region	4045
@NP	spinal cord	4068
@NP	There	4081
@NP	a strong expression of GFAP in the lesion	4091
@NP	a strong expression	4091
@NP	GFAP in the lesion	4114
@NP	GFAP	4114
@NP	the lesion	4122
@NP	the GFAP + areas	4138
@NP	the GFAP	4138
@NP	areas	4148
@NP	the exogenous grafting cells	4163
@NP	Fig. 3 .	4194
@NP	Fig.	4194
@NP	3	4199
@NP	The rat motor function behavior	4202
@NP	the treadmill	4237
@NP	ChABC treatment and OMPC transplantation	4257
@NP	ChABC treatment	4257
@NP	OMPC transplantation	4277
@NP	-LRB- A -RRB- For the intact animal , the treadmill walking	4299
@NP	-LRB- A -RRB-	4299
@NP	the intact animal , the treadmill walking	4307
@NP	the intact animal	4307
@NP	the treadmill walking	4326
@NP	the treadmill	4326
@NP	a recorded graph	4358
@NP	a standard reference gait	4381
@NP	the servo-controlled BWS	4414
@NP	the treadmill walking gaits of left and right hind limbs	4440
@NP	the treadmill	4440
@NP	gaits of left and right hind limbs	4462
@NP	gaits	4462
@NP	left and right hind limbs	4471
@NP	-LRB- B -RRB-	4523
@NP	The walking measure data from the left and right hind limbs of rats	4527
@NP	The walking measure data	4527
@NP	the left and right hind limbs of rats	4557
@NP	the left and right hind limbs	4557
@NP	rats	4590
@NP	spinal cord injury	4600
@NP	treatment	4637
@NP	-LRB- C -RRB- The kinematic trajectory of combined treatment	4660
@NP	The kinematic trajectory	4664
@NP	combined treatment	4692
@NP	ChABC delivery and OMPC graft	4712
@NP	ChABC delivery	4712
@NP	OMPC graft	4731
@NP	the normal trajectory	4753
@NP	-LRB- D -RRB-	4776
@NP	The photo of sham control -LRB- non-repair -RRB- and -LRB- E -RRB- post-repair	4780
@NP	The photo of sham control -LRB- non-repair -RRB-	4780
@NP	The photo	4780
@NP	sham control	4793
@NP	non-repair	4807
@NP	E	4824
@NP	post-repair	4827
@NP	spinal cord injury	4848
@NP	injured axons	4868
@NP	The cellular and molecular mechanisms of regenerative failure after SCI	4899
@NP	The cellular and molecular mechanisms	4899
@NP	regenerative failure after SCI	4940
@NP	regenerative failure	4940
@NP	SCI	4967
@NP	there	4995
@NP	no significant effect on the motor function improvement -LSB- 10 -RSB-	5005
@NP	no significant effect	5005
@NP	the motor function improvement -LSB- 10 -RSB-	5030
@NP	the motor function improvement	5030
@NP	10 -RSB-	5062
@NP	SCI	5073
@NP	a cascade of cellular and molecular responses	5078
@NP	a cascade	5078
@NP	cellular and molecular responses	5091
@NP	the formation of a dense astroglial scar at the lesion site	5136
@NP	the formation	5136
@NP	a dense astroglial scar at the lesion site	5153
@NP	a dense astroglial scar	5153
@NP	the lesion site	5180
@NP	Chondroitin sulfate proteoglycan -LRB- CSPG -RRB-	5197
@NP	Chondroitin sulfate proteoglycan	5197
@NP	CSPG	5231
@NP	a major component of glial scars in injured spinal cords -LSB- 10,12,13 -RSB-	5240
@NP	a major component	5240
@NP	glial scars in injured spinal cords -LSB- 10,12,13 -RSB-	5261
@NP	glial scars	5261
@NP	injured spinal cords -LSB- 10,12,13 -RSB-	5276
@NP	injured spinal cords	5276
@NP	10,12,13 -RSB-	5298
@NP	Chondroitinase ABC -LRB- ChABC -RRB-	5309
@NP	Chondroitinase ABC	5309
@NP	ChABC	5329
@NP	a bacteria enzyme	5339
@NP	chondroitin sulfate proteoglycan glycosaminoglycan -LRB- CSPG-GAG -RRB-	5377
@NP	chondroitin sulfate proteoglycan glycosaminoglycan	5377
@NP	CSPG-GAG	5429
@NP	axonal sprouting and functional recovery in various animal models -LSB- 9 -RSB-	5461
@NP	axonal sprouting and functional recovery	5461
@NP	various animal models	5505
@NP	we	5546
@NP	the digested products	5565
@NP	ChABC treatment and a small number of axonal fibers	5603
@NP	ChABC treatment	5603
@NP	a small number of axonal fibers	5623
@NP	a small number	5623
@NP	axonal fibers	5641
@NP	HRP-tracer	5672
@NP	the spinal cord lesion area -LSB- 8 -RSB-	5690
@NP	the spinal cord lesion area	5690
@NP	8 -RSB-	5719
@NP	Our previous study	5723
@NP	sustained delivery	5756
@NP	ChABC	5778
@NP	intrathecal catheter -LRB- 1 U/ml , injection volume 6µl for one animal -RRB-	5788
@NP	intrathecal catheter	5788
@NP	1 U/ml , injection volume 6µl for one animal	5810
@NP	1 U/ml , injection volume 6µl	5810
@NP	1 U/ml , injection volume	5810
@NP	1 U/ml	5810
@NP	injection volume	5818
@NP	one animal	5843
@NP	the fractional functional behavior in SCI rats	5869
@NP	the fractional functional behavior	5869
@NP	SCI rats	5907
@NP	the BBB scale	5929
@NP	we	5953
@NP	the limited functional recovery	5974
@NP	the absence	6022
@NP	a myelin sheath , which surrounded the regrown axons within the lesion site	6037
@NP	a myelin sheath	6037
@NP	the regrown axons	6071
@NP	the lesion site	6096
@NP	Cellular transplantation	6113
@NP	a potential therapeutic strategy	6163
@NP	neural regeneration	6207
@NP	SCI	6230
@NP	Previous reports	6235
@NP	transplantation of olfactory ensheathing cells -LRB- OECs -RRB- or Schwann cells	6272
@NP	transplantation	6272
@NP	olfactory ensheathing cells -LRB- OECs -RRB- or Schwann cells	6291
@NP	OECs	6320
@NP	the sprouting of axons across the lesion site in spinal cord	6355
@NP	the sprouting	6355
@NP	axons across the lesion site in spinal cord	6372
@NP	axons	6372
@NP	the lesion site in spinal cord	6385
@NP	the lesion site	6385
@NP	spinal cord	6404
@NP	remyelination	6427
@NP	the re-grown axons -LSB- 3,18 -RSB-	6448
@NP	the re-grown axons	6448
@NP	3,18 -RSB-	6468
@NP	the combination of cell transplantation with ChABC	6481
@NP	the combination	6481
@NP	cell transplantation with ChABC	6500
@NP	cell transplantation	6500
@NP	ChABC	6526
@NP	a potent therapeutic strategy for SCI	6539
@NP	a potent therapeutic strategy	6539
@NP	SCI	6573
@NP	the combined therapeutic effects	6590
@NP	stem cell transplantation and ChABC treatment in SCI rats	6626
@NP	stem cell transplantation and ChABC treatment	6626
@NP	SCI rats	6675
@NP	olfactory mucosa progenitor cells -LRB- OMPCs -RRB-	6685
@NP	olfactory mucosa progenitor cells	6685
@NP	OMPCs	6720
@NP	the adult rat olfactory mucosa of intact rats -LRB- 250 -- 300 g -RRB-	6746
@NP	the adult rat olfactory mucosa	6746
@NP	intact rats -LRB- 250 -- 300 g -RRB-	6780
@NP	intact rats	6780
@NP	250 -- 300 g	6793
@NP	250	6793
@NP	300 g	6797
@NP	neurobasal medium	6820
@NP	B27 supplement	6849
@NP	bFGF 20 ng/ml	6865
@NP	heparin 5 g/ml	6880
@NP	EGF 20 ng/ml -LRB- Invitrogen -RRB-	6896
@NP	EGF	6896
@NP	20 ng/ml -LRB- Invitrogen -RRB-	6900
@NP	Invitrogen	6910
@NP	glial cell line-derived neurotrophin factor -LRB- GDNF -RRB- 10 ng/ml	6923
@NP	glial cell line-derived neurotrophin factor	6923
@NP	GDNF	6968
@NP	10 ng/ml	6974
@NP	antibiotics for 5 -- 7 days to generate neurosphere suspension	6987
@NP	antibiotics for 5	6987
@NP	antibiotics	6987
@NP	5	7003
@NP	7 days to generate neurosphere suspension	7005
@NP	7 days	7005
@NP	neurosphere suspension	7024
@NP	The neurospheres with a diameter of 150 -- 200µm	7048
@NP	The neurospheres	7048
@NP	a diameter of 150 -- 200µm	7070
@NP	a diameter of 150	7070
@NP	a diameter	7070
@NP	150	7084
@NP	200µm	7088
@NP	them	7124
@NP	0.025 % trypsin -- EDTA in Ca2 + -	7134
@NP	0.025 % trypsin	7134
@NP	EDTA in Ca2	7149
@NP	EDTA	7149
@NP	Ca2	7157
@NP	+	7160
@NP	Mg2	7167
@NP	+	7170
@NP	free solution -LRB- GIBCO , Grand Island , NY -RRB-	7172
@NP	free solution	7172
@NP	GIBCO	7187
@NP	Grand Island	7194
@NP	NY	7208
@NP	5 min	7216
@NP	them	7239
@NP	solution	7266
@NP	OMPCs	7276
@NP	37 ◦ C	7300
@NP	5 % CO2 in air , for 2 weeks subcultured	7312
@NP	5 % CO2	7312
@NP	air	7322
@NP	2 weeks subcultured	7331
@NP	2 weeks	7331
@NP	the incubation in neurobasal medium	7362
@NP	the incubation	7362
@NP	neurobasal medium	7380
@NP	OMPCs	7399
@NP	cellular characterization	7426
@NP	immunocytochemistry assay	7455
@NP	The neurospheres with a diameter of 150 -- 200µm	7482
@NP	The neurospheres	7482
@NP	a diameter of 150 -- 200µm	7504
@NP	a diameter of 150	7504
@NP	a diameter	7504
@NP	150	7518
@NP	200µm	7522
@NP	the pre-coated poly-l-lysine -LRB- 10µg/ml -RRB- dish	7543
@NP	10µg/ml	7573
@NP	our defined differentiation medium	7605
@NP	B27 supplement solution and laminin -LRB- 5µg/ml -RRB-	7641
@NP	B27 supplement solution and laminin	7641
@NP	B27 supplement solution	7641
@NP	laminin	7669
@NP	5µg/ml	7678
@NP	the DMEM/F12 culture medium -LRB- Invitrogen -RRB-	7700
@NP	the DMEM/F12 culture medium	7700
@NP	Invitrogen	7729
@NP	every 2 days	7759
@NP	7 days of incubation	7777
@NP	7 days	7777
@NP	incubation	7787
@NP	we	7799
@NP	the cells	7808
@NP	acetone/absolute alcohol -LRB- 1:1 -RRB-	7823
@NP	acetone/absolute alcohol	7823
@NP	1:1	7849
@NP	4 ◦ C for 20 min	7857
@NP	4 ◦ C	7857
@NP	20 min	7866
@NP	the solution to wash the cells twice -LRB- 5 min each time -RRB-	7886
@NP	the solution to wash the cells twice	7886
@NP	the cells	7907
@NP	5 min each time	7924
@NP	5 min	7924
@NP	each time	7930
@NP	The cells	7942
@NP	0.2 % Triton-X 100 -LRB- Sigma , St.	7968
@NP	0.2 % Triton-X	7968
@NP	100 -LRB- Sigma , St.	7982
@NP	100	7982
@NP	Sigma	7987
@NP	St.	7994
@NP	Louis , MO -RRB- in PBS at room temperature for 30 min .	7998
@NP	Louis , MO -RRB- in PBS at room	7998
@NP	Louis , MO -RRB-	7998
@NP	Louis	7998
@NP	PBS at room	8010
@NP	PBS	8010
@NP	room	8017
@NP	temperature for 30 min	8022
@NP	temperature	8022
@NP	30 min	8038
@NP	2 % BSA -LRB- bovine serum albumin -RRB- in PBS	8060
@NP	2 % BSA -LRB- bovine serum albumin -RRB-	8060
@NP	2 % BSA	8060
@NP	bovine serum albumin	8068
@NP	PBS	8093
@NP	a blocking solution at room temperature for 1 h.	8109
@NP	a blocking solution	8109
@NP	room temperature for 1 h.	8132
@NP	room temperature	8132
@NP	1 h.	8153
@NP	Primary antibodies	8158
@NP	1 % BSA	8195
@NP	PBS	8205
@NP	O4 -LRB- 1:500 -RRB-	8220
@NP	O4	8220
@NP	1:500	8224
@NP	NG2 -LRB- 1:500 -RRB-	8235
@NP	NG2	8235
@NP	1:500	8240
@NP	a marker for oligodendrocyte progenitor cells	8248
@NP	a marker	8248
@NP	oligodendrocyte progenitor cells	8261
@NP	GFAP -LRB- 1:500 -RRB- a marker of astrocytes	8295
@NP	GFAP -LRB- 1:500 -RRB-	8295
@NP	GFAP	8295
@NP	1:500	8301
@NP	a marker of astrocytes	8308
@NP	a marker	8308
@NP	astrocytes	8320
@NP	peripherin	8336
@NP	1:500	8348
@NP	a cellular marker of developing neurons	8356
@NP	a cellular marker	8356
@NP	developing neurons	8377
@NP	all from Chemicon	8397
@NP	all	8397
@NP	Chemicon	8406
@NP	Tamecula , CA	8416
@NP	Tamecula	8416
@NP	CA	8426
@NP	We	8431
@NP	five regions	8443
@NP	each	8459
@NP	the immunopositive cells	8481
@NP	them	8517
@NP	all of the cells	8527
@NP	all	8527
@NP	the cells	8534
@NP	each region	8549
@NP	Fig. 1	8574
@NP	OMPCs	8587
@NP	10 ng/ml	8610
@NP	GDNF-containing medium	8619
@NP	the cell	8652
@NP	a branching neurite , oligodendrocyte progenitor cell-like morphology	8665
@NP	a branching neurite	8665
@NP	oligodendrocyte progenitor cell-like morphology	8686
@NP	cells	8739
@NP	extended neurites	8755
@NP	A large number of OMPCs	8774
@NP	A large number	8774
@NP	OMPCs	8792
@NP	NG2 -LRB- a marker of oligodendrocyte progenitor cells -RRB-	8808
@NP	NG2	8808
@NP	a marker of oligodendrocyte progenitor cells	8813
@NP	a marker	8813
@NP	oligodendrocyte progenitor cells	8825
@NP	O4 -LRB- for mature oligodendrocytes -RRB-	8863
@NP	O4	8863
@NP	mature oligodendrocytes	8871
@NP	Representative photomicrographs	8897
@NP	OMPCs	8945
@NP	oligodendrocyte progenitor cells expressing NG2 -LRB- red -RRB-	8961
@NP	oligodendrocyte progenitor cells	8961
@NP	NG2 -LRB- red -RRB-	9005
@NP	NG2	9005
@NP	red	9010
@NP	O4-immunopositive cells -LRB- green -RRB-	9036
@NP	O4-immunopositive cells	9036
@NP	the role of grafted OMPCs in regeneration of SCI rats	9087
@NP	the role	9087
@NP	grafted OMPCs in regeneration of SCI rats	9099
@NP	grafted OMPCs	9099
@NP	regeneration of SCI rats	9116
@NP	regeneration	9116
@NP	SCI rats	9132
@NP	we	9142
@NP	BrdU -LRB- 5mM , incubated for 24 h -RRB-	9150
@NP	BrdU	9150
@NP	5mM , incubated for 24 h	9156
@NP	5mM	9156
@NP	24 h	9175
@NP	the OMPCs	9190
@NP	transplantation	9207
@NP	The BrdU-labeled OMPCs	9224
@NP	The	9224
@NP	OMPCs	9241
@NP	the parenchyma of injured site of spinal cord	9270
@NP	the parenchyma	9270
@NP	injured site of spinal cord	9288
@NP	injured site	9288
@NP	spinal cord	9304
@NP	a Hamilton syringe	9322
@NP	ChABC delivery	9347
@NP	8 weeks	9369
@NP	the rats	9378
@NP	100 ml PBS and 300 ml cold 4 % paraformaldehyde solution ; and pH 7.4	9406
@NP	100 ml PBS	9406
@NP	300 ml cold 4 % paraformaldehyde solution	9421
@NP	300 ml	9421
@NP	cold 4 % paraformaldehyde solution	9428
@NP	pH 7.4	9467
@NP	Spinal cord tissues from both lesion sites and noninjured spinal cords	9475
@NP	Spinal cord tissues	9475
@NP	both lesion sites and noninjured spinal cords	9500
@NP	both lesion sites	9500
@NP	noninjured spinal cords	9522
@NP	15 mm from the lesion area in both the proximal and caudal stumps	9547
@NP	15 mm	9547
@NP	the lesion area in both the proximal and caudal stumps	9557
@NP	the lesion area	9557
@NP	both the proximal and caudal stumps	9576
@NP	4 % paraformaldehyde solution for an additional 12 h.	9644
@NP	4 % paraformaldehyde solution	9644
@NP	an additional 12 h.	9677
@NP	The cryosection -LRB- 20µm -RRB-	9697
@NP	The cryosection	9697
@NP	20µm	9714
@NP	the immunochemistry procedure	9744
@NP	incubation	9785
@NP	5 % bovine serum albumin	9801
@NP	PBS for 30 min , monoclonal antibody to GAP-43 -LRB- 1:1000 ; Sigma , St.	9828
@NP	PBS	9828
@NP	30 min , monoclonal antibody to GAP-43 -LRB- 1:1000 ; Sigma , St.	9836
@NP	30 min	9836
@NP	monoclonal antibody to GAP-43 -LRB- 1:1000 ; Sigma , St.	9844
@NP	monoclonal antibody to GAP-43 -LRB- 1:1000 ;	9844
@NP	monoclonal antibody	9844
@NP	GAP-43 -LRB- 1:1000 ;	9867
@NP	GAP-43	9867
@NP	1:1000	9875
@NP	Sigma , St.	9883
@NP	Louis , MO -RRB-	9894
@NP	Louis	9894
@NP	BrdU -LRB- 1:5000 ; Seikagaku Corporation -RRB-	9906
@NP	BrdU	9906
@NP	1:5000 ; Seikagaku Corporation	9912
@NP	1:5000	9912
@NP	Seikagaku Corporation	9920
@NP	GFAP -LRB- 1:1000 ; Sigma -RRB-	9944
@NP	GFAP	9944
@NP	1:1000 ; Sigma	9950
@NP	1:1000	9950
@NP	Sigma	9958
@NP	NG2	9969
@NP	1:1000 ; DAKO	9974
@NP	1:1000	9974
@NP	DAKO	9982
@NP	primary antibodies	10001
@NP	Appropriate secondary antibody plus ABC procedure	10021
@NP	Appropriate secondary antibody	10021
@NP	ABC procedure	10057
@NP	peroxidase staining for GAP-43	10085
@NP	peroxidase staining	10085
@NP	GAP-43	10109
@NP	Anti-mouse	10117
@NP	anti-rabbit and antigoat secondary antibodies	10129
@NP	Alexa Flour-488 and 568	10189
@NP	Alexa Flour-488	10189
@NP	568	10209
@NP	other signals such as GFAP , NG2 , and BrdU	10233
@NP	other signals	10233
@NP	GFAP , NG2 , and BrdU	10255
@NP	GFAP	10255
@NP	NG2	10261
@NP	BrdU	10270
@NP	the results shown in Fig. 2	10283
@NP	the results	10283
@NP	Fig. 2	10304
@NP	the BrdU + cells	10312
@NP	the BrdU	10312
@NP	cells	10322
@NP	NG2	10351
@NP	the lesion site -LRB- Fig. 2A -RRB-	10359
@NP	the lesion site	10359
@NP	Fig. 2A	10376
@NP	8 weeks of transplantation	10391
@NP	8 weeks	10391
@NP	transplantation	10402
@NP	The grafted OMPCs	10419
@NP	the fate specific cell lineages	10476
@NP	These OMPCs	10509
@NP	the types of progenitor	10537
@NP	the types	10537
@NP	progenitor	10550
@NP	NG2 + cells , Fig. 2B and C	10562
@NP	NG2 + cells	10562
@NP	Fig. 2B and C	10574
@NP	the spinal cord lesion region	10596
@NP	Fewer GFAP + cells	10627
@NP	Fewer GFAP	10627
@NP	cells	10639
@NP	BrdU + cells near spinal cord lesion regions	10661
@NP	BrdU + cells	10661
@NP	spinal cord lesion regions	10678
@NP	OMPC transplantation -LRB- Fig. 2D -- F -RRB-	10711
@NP	OMPC transplantation	10711
@NP	Fig. 2D -- F	10733
@NP	Fig. 2D	10733
@NP	F	10741
@NP	higher magnification images	10770
@NP	the regions in Fig. 2D	10803
@NP	the regions	10803
@NP	Fig. 2D	10818
@NP	it	10827
@NP	BrdU + cells -LRB- red -RRB-	10849
@NP	BrdU + cells	10849
@NP	red	10862
@NP	the spinal cord transection site	10884
@NP	these cells	10921
@NP	astrocytes	10960
@NP	GFAP -LRB- green -RRB-	10983
@NP	GFAP	10983
@NP	Our experimental results	10997
@NP	these grafted OMPCs	11038
@NP	their differentiated courses	11090
@NP	their	11090
@NP	courses	11111
@NP	OMPCs	11128
@NP	the pattern of oligodendrocyte progenitor cells	11150
@NP	the pattern	11150
@NP	oligodendrocyte progenitor cells	11165
@NP	NG2	11209
@NP	the spinal cord lesion region 8 weeks	11220
@NP	the spinal cord lesion region	11220
@NP	8 weeks	11250
@NP	transplantation	11264
@NP	we	11290
@NP	the possibility	11309
@NP	the local environment following injury	11330
@NP	the differentiation date for the grafted OMPCs	11390
@NP	the differentiation date	11390
@NP	the grafted OMPCs	11419
@NP	the previous studies	11449
@NP	cell therapy	11485
@NP	the sprouting of axons across the spinal cord lesion site	11513
@NP	the sprouting	11513
@NP	axons across the spinal cord lesion site	11530
@NP	axons	11530
@NP	the spinal cord lesion site	11543
@NP	remyelination	11582
@NP	the re-grown axons	11603
@NP	recent progress in stem cell therapy	11628
@NP	recent progress	11628
@NP	stem cell therapy	11647
@NP	the timing of stem cell transplantation	11666
@NP	the timing	11666
@NP	stem cell transplantation	11680
@NP	the survival and differentiation	11721
@NP	grafted cells	11757
@NP	functional improvement in terms of the injured spinal cord microenvironment	11775
@NP	functional improvement	11775
@NP	terms of the injured spinal cord microenvironment	11801
@NP	terms	11801
@NP	the injured spinal cord microenvironment	11810
@NP	The results	11852
@NP	theOMPCsfollowing GDNF-induction	11879
@NP	the mature cell lineages in vivo	11939
@NP	the mature cell lineages	11939
@NP	vivo	11967
@NP	We	11973
@NP	the extracellular matrices -LRB- ECMs -RRB-	11994
@NP	the extracellular matrices	11994
@NP	ECMs	12022
@NP	factors within injured tissues in spinal cord	12032
@NP	factors	12032
@NP	injured tissues in spinal cord	12047
@NP	injured tissues	12047
@NP	spinal cord	12066
@NP	the differentiation of grafted OMPCs	12094
@NP	the differentiation	12094
@NP	grafted OMPCs	12117
@NP	Substantial evidence	12132
@NP	complex ECMs and factors	12184
@NP	nervous system plasticity regulation	12225
@NP	response	12269
@NP	injuries	12281
@NP	ECM component modification	12291
@NP	axonal regeneration	12351
@NP	the endogenous neural progenitor cells	12383
@NP	the destroyed cells	12433
@NP	the spinal cord lesion region -LSB- 11 -RSB-	12460
@NP	the spinal cord lesion region	12460
@NP	11 -RSB-	12491
@NP	the detailed interactions	12502
@NP	grafted OMPC and local environment of injured spinal cords	12536
@NP	grafted OMPC	12536
@NP	local environment of injured spinal cords	12553
@NP	local environment	12553
@NP	injured spinal cords	12574
@NP	our next study	12630
@NP	our pilot study	12649
@NP	the motor function	12666
@NP	BBB	12707
@NP	Neither ChABC alone nor OMPC	12712
@NP	ChABC alone	12720
@NP	OMPC	12736
@NP	scale 4 , which indicates the weight bearing ability	12758
@NP	scale 4	12758
@NP	the weight bearing ability	12783
@NP	contrast	12814
@NP	the	12824
@NP	treatment -LRB- ChABC + OMPC -RRB-	12836
@NP	treatment	12836
@NP	ChABC + OMPC	12847
@NP	ChABC	12847
@NP	OMPC	12854
@NP	scale 4 since the third week -LRB- Fig	12868
@NP	scale 4	12868
@NP	the third week -LRB- Fig	12882
@NP	the third week	12882
@NP	Fig	12898
@NP	S1	12903
@NP	the following study	12918
@NP	the combine treatment	12953
@NP	The walking kinematic trajectories of injured and repaired rats	13551
@NP	The walking kinematic trajectories of injured	13551
@NP	The walking kinematic trajectories	13551
@NP	injured	13589
@NP	repaired rats	13601
@NP	the treadmill	13647
@NP	the servo-controlled body weight support -LRB- BWS -RRB- -LSB- 4,6,7,17 -RSB-	13667
@NP	the servo-controlled body weight support -LRB- BWS -RRB-	13667
@NP	the servo-controlled body weight support	13667
@NP	BWS	13709
@NP	4,6,7,17 -RSB-	13715
@NP	brief	13729
@NP	all experimental rats	13736
@NP	a treadmill	13773
@NP	a period of 1 week as treadmill training	13802
@NP	a period	13802
@NP	1 week as treadmill training	13814
@NP	1 week	13814
@NP	treadmill training	13824
@NP	all experimental procedures	13861
@NP	One week	13890
@NP	both the sham control -LRB- SCI alone -RRB- and treatment groups	13906
@NP	the sham control -LRB- SCI alone -RRB- and treatment groups	13911
@NP	the sham control -LRB- SCI alone -RRB-	13911
@NP	the sham control	13911
@NP	SCI	13929
@NP	treatment groups	13944
@NP	the treadmill	13976
@NP	their walking gait	14002
@NP	Locomotor training	14022
@NP	daily sessions -LRB- 5 days/week -RRB- of 20 min bipedal treadmill training	14054
@NP	daily sessions -LRB- 5 days/week -RRB-	14054
@NP	daily sessions	14054
@NP	5 days/week	14070
@NP	20 min bipedal treadmill training	14086
@NP	20 min	14086
@NP	Bipedal training	14121
@NP	a standard procedure in previous experiments	14155
@NP	a standard procedure	14155
@NP	previous experiments	14179
@NP	complete spinal cord transection	14206
@NP	treatments -LSB- 14 -RSB-	14248
@NP	treatments	14248
@NP	14 -RSB-	14260
@NP	A hollow cylinder made of heavy cloth	14265
@NP	A hollow cylinder	14265
@NP	heavy cloth	14291
@NP	the end of the BWS arm	14317
@NP	the end	14317
@NP	the BWS arm	14328
@NP	the rats	14351
@NP	their head and upper body	14374
@NP	their hind limbs	14407
@NP	their weight	14434
@NP	the moving treadmill belt	14450
@NP	This procedure	14477
@NP	a bipedal stance	14502
@NP	the rats	14532
@NP	a harness	14564
@NP	The rate of treadmill training	14575
@NP	The rate	14575
@NP	treadmill training	14587
@NP	7 cm/s	14617
@NP	a maximum of 21 cm/s for 20 min	14636
@NP	a maximum	14636
@NP	21 cm/s for 20 min	14649
@NP	21 cm/s	14649
@NP	20 min	14661
@NP	training	14675
@NP	the rats	14685
@NP	20 cm/s for 20 min	14715
@NP	20 cm/s	14715
@NP	20 min	14727
@NP	the third week of training	14737
@NP	the third week	14737
@NP	training	14755
@NP	A sweet cereal reward	14765
@NP	each rat	14800
@NP	the bipedal training sessions	14815
@NP	A series	14846
@NP	parameters	14858
@NP	the gait timing	14880
@NP	the characteristics of limb trajectory	14897
@NP	the characteristics	14897
@NP	limb trajectory	14920
@NP	the spatial and temporal features of the kinematic patterns	14941
@NP	the spatial and temporal features	14941
@NP	the kinematic patterns	14978
@NP	each animal	15019
@NP	A gait cycle	15032
@NP	the time interval between two successive paw contacts	15060
@NP	the time interval	15060
@NP	two successive paw contacts	15086
@NP	one limb	15117
@NP	Thirty successive paw contacts and consistent hind limb gait cycles	15127
@NP	Thirty successive paw contacts	15127
@NP	consistent hind limb gait cycles	15162
@NP	each animal	15223
@NP	Footfall patterns	15236
@NP	the coupling between the hind limbs -LSB- 5,19,22 -RSB-	15275
@NP	the coupling	15275
@NP	the hind limbs -LSB- 5,19,22 -RSB-	15296
@NP	the hind limbs	15296
@NP	5,19,22 -RSB-	15312
@NP	the results in Fig. 3	15329
@NP	the results	15329
@NP	Fig. 3	15344
@NP	the treadmill walking patterns of repaired rats -LRB- Fig. 3C -RRB-	15352
@NP	the treadmill	15352
@NP	patterns of repaired rats -LRB- Fig. 3C -RRB-	15374
@NP	patterns	15374
@NP	repaired rats -LRB- Fig. 3C -RRB-	15386
@NP	repaired rats	15386
@NP	Fig. 3C	15401
@NP	that of the normal ones -LRB- Fig. 3A -RRB-	15426
@NP	that	15426
@NP	the normal ones -LRB- Fig. 3A -RRB-	15434
@NP	the normal ones	15434
@NP	Fig. 3A	15451
@NP	the magnitude	15470
@NP	the effect	15487
@NP	the right hind limbs	15511
@NP	repaired rats -LRB- Fig. 3E , marked with a red circle -RRB-	15535
@NP	repaired rats	15535
@NP	Fig. 3E , marked with a red circle	15550
@NP	Fig. 3E	15550
@NP	marked with a red circle	15559
@NP	marked	15559
@NP	a red circle	15571
@NP	summary	15604
@NP	the movement pattern	15613
@NP	combined treated -LRB- ChABC with OMPC transplantation -RRB- rats	15637
@NP	ChABC with OMPC transplantation	15655
@NP	ChABC	15655
@NP	OMPC transplantation	15666
@NP	the intact rats -LRB- Fig. 3A -RRB-	15704
@NP	the intact rats	15704
@NP	Fig. 3A	15721
@NP	Stepping of treated rats on the treadmill	15731
@NP	Stepping	15731
@NP	treated rats on the treadmill	15743
@NP	treated rats	15743
@NP	the treadmill	15759
@NP	short , well-coordinated steps , small variability and minimal toe dragging	15810
@NP	short , well-coordinated steps	15810
@NP	small variability	15841
@NP	minimal toe dragging	15863
@NP	minimal toe	15863
@NP	Kinematic gait analysis and paw-spread	15885
@NP	Kinematic gait analysis	15885
@NP	paw-spread	15913
@NP	small changes	15958
@NP	hind limb function	15975
@NP	this study	15998
@NP	similar treadmill training	16010
@NP	the difference between treated and untreated SCI rats	16057
@NP	the difference between treated and untreated SCI	16057
@NP	the difference	16057
@NP	treated and untreated SCI	16080
@NP	The gait patterns	16112
@NP	the treated rats following OMPC transplantation and ChABC delivery	16133
@NP	the treated rats	16133
@NP	OMPC transplantation and ChABC delivery	16160
@NP	OMPC transplantation	16160
@NP	ChABC delivery	16185
@NP	the patterns of intact rats	16213
@NP	the patterns	16213
@NP	intact rats	16229
@NP	the untreated group	16254
@NP	these grafted OMPCs	16284
@NP	mature cell phenotypes	16321
@NP	they	16345
@NP	the spinal cord lesion region	16382
@NP	the functional improvement	16416
@NP	gait analysis on the treadmill	16462
@NP	gait analysis	16462
@NP	the treadmill	16479
@NP	The hypothesis associated with immunomodulation of OMPC transplantation	16494
@NP	The hypothesis	16494
@NP	immunomodulation of OMPC transplantation	16525
@NP	immunomodulation	16525
@NP	OMPC transplantation	16545
@NP	detail in future	16590
@NP	detail	16590
@NP	future	16600
@NP	The distinct effects of ChABC	16608
@NP	The distinct effects	16608
@NP	ChABC	16632
@NP	the timing of delivery	16661
@NP	the timing	16661
@NP	delivery	16675
@NP	SCI	16691
@NP	CSPGs	16708
@NP	the lesion site	16749
@NP	Sustained delivery	16766
@NP	ChABC with the safety and the lowest dose via intrathecal catheter	16788
@NP	ChABC with the safety	16788
@NP	ChABC	16788
@NP	the safety	16799
@NP	the lowest dose via intrathecal catheter	16814
@NP	the lowest dose	16814
@NP	intrathecal catheter	16834
@NP	injured spinal cord	16882
@NP	fractional motor functions	16914
@NP	8 -RSB-	16942
@NP	the substrate modification	16960
@NP	the outcome of macrophage attack	16997
@NP	the outcome	16997
@NP	macrophage attack	17012
@NP	in vivo ChABC treatment within the lesion site	17035
@NP	in vivo ChABC treatment	17035
@NP	the lesion site	17066
@NP	CNS regeneration	17107
@NP	macrophage-induced retraction of axons -LSB- 2 -RSB-	17138
@NP	macrophage-induced retraction	17138
@NP	axons -LSB- 2 -RSB-	17171
@NP	axons	17171
@NP	2 -RSB-	17178
@NP	ChABC	17182
@NP	the local environment of lesion region	17205
@NP	the local environment	17205
@NP	lesion region	17230
@NP	spinal cord	17247
@NP	intrinsic sensory neurons growth capacity	17270
@NP	the dorsal columns -LSB- 2,15 -RSB-	17315
@NP	the dorsal columns	17315
@NP	2,15 -RSB-	17335
@NP	several factors	17351
@NP	the effect of ChABC in vivo.ChABCis	17373
@NP	the effect	17373
@NP	ChABC in vivo.ChABCis	17387
@NP	ChABC	17387
@NP	vivo.ChABCis	17396
@NP	its enzymatic activity	17440
@NP	3	17478
@NP	5 days at 37 ◦ C -LSB- 20 -RSB-	17480
@NP	5 days	17480
@NP	The infusion frequency of ChABC via intrathecal catheter or injection	17502
@NP	The infusion frequency	17502
@NP	ChABC via intrathecal catheter or injection	17528
@NP	ChABC	17528
@NP	intrathecal catheter or injection	17538
@NP	the least 2 -- 3 days -LSB- 20 -RSB-	17591
@NP	the least 2	17591
@NP	3 days -LSB- 20 -RSB-	17603
@NP	3 days	17603
@NP	20 -RSB-	17611
@NP	There	17616
@NP	need	17639
@NP	clinically viable delivery methods for the	17654
@NP	clinically viable delivery methods	17654
@NP	the	17693
@NP	ChABC	17745
@NP	Cell-based therapy	17752
@NP	an attractive strategy for spinal cord injury or diseases	17780
@NP	an attractive strategy	17780
@NP	spinal cord injury or diseases	17807
@NP	spinal cord injury	17807
@NP	diseases	17829
@NP	the loss of both neurons and glial cells	17850
@NP	the loss	17850
@NP	both neurons and glial cells	17862
@NP	neurons	17867
@NP	glial cells	17879
@NP	SCI	17897
@NP	cell-based strategies for reconstituting the injured spinal cord	17908
@NP	cell-based strategies	17908
@NP	the injured spinal cord	17949
@NP	damaged cell types	18007
@NP	the rapid pace of advance in our understanding , cell-based therapy	18031
@NP	the rapid pace	18031
@NP	advance in our understanding , cell-based therapy	18049
@NP	advance	18049
@NP	our understanding , cell-based therapy	18060
@NP	our understanding	18060
@NP	cell-based therapy	18079
@NP	the only one role	18105
@NP	cellular replacement in SCI	18127
@NP	cellular replacement	18127
@NP	SCI	18151
@NP	Cell transplants	18156
@NP	motor function	18181
@NP	a combination	18209
@NP	the activation of endogenous stem/progenitor cells	18311
@NP	the activation	18311
@NP	endogenous stem/progenitor cells	18329
@NP	The grafted cells	18363
@NP	immunomodulatory properties -LSB- 16,21 -RSB-	18413
@NP	immunomodulatory properties	18413
@NP	16,21 -RSB-	18442
@NP	it	18456
@NP	the grafted cells	18490
@NP	axonal elongation	18524
@NP	functional recovery	18554
@NP	our studies	18578
@NP	the reason	18591
@NP	the OMPCs	18607
@NP	their NG2 immunoreactivity	18626
@NP	oligodendrocyte progenitor cells -LRB- OPCs -RRB- at long survivals	18656
@NP	oligodendrocyte progenitor cells -LRB- OPCs -RRB-	18656
@NP	oligodendrocyte progenitor cells	18656
@NP	OPCs	18690
@NP	long survivals	18699
@NP	8 weeks of transplantation	18726
@NP	8 weeks	18726
@NP	transplantation	18737
@NP	Previous	18775
@NP	progenitor cells	18809
@NP	growth factors	18840
@NP	factors , and neurotrophic factors	18871
@NP	factors	18871
@NP	neurotrophic factors	18884
@NP	neurogenesis and synaptic plasticity	18917
@NP	their development	18961
@NP	It	18980
@NP	quantitative techniques	19009
@NP	motor function	19043
@NP	treatment	19064
@NP	The locomotor functions	19075
@NP	swing velocity , step height , hindlimb coordination , and ability	19107
@NP	swing velocity	19107
@NP	step height	19123
@NP	hindlimb coordination	19136
@NP	ability	19163
@NP	body weight	19182
@NP	Basso , Beattie , and Bresnahan -LRB- BBB -RRB- scale analysis	19222
@NP	Basso	19222
@NP	Beattie	19229
@NP	Bresnahan -LRB- BBB -RRB- scale analysis	19242
@NP	Bresnahan	19242
@NP	BBB	19253
@NP	scale analysis	19258
@NP	Robotic gait analysis of bipedal treadmill	19274
@NP	Robotic gait analysis	19274
@NP	bipedal treadmill	19299
@NP	an objective	19328
@NP	rapid behavioral assessment of locomotor function -LSB- 1,14 -RSB-	19345
@NP	rapid behavioral assessment	19345
@NP	locomotor function -LSB- 1,14 -RSB-	19376
@NP	locomotor function	19376
@NP	1,14 -RSB-	19396
@VP	has been demonstrated to digest the glycosaminoglycan	1098
@VP	been demonstrated to digest the glycosaminoglycan	1102
@VP	demonstrated to digest the glycosaminoglycan	1107
@VP	to digest the glycosaminoglycan	1120
@VP	digest the glycosaminoglycan	1123
@VP	to promote axonal regrowth across the injured site	1177
@VP	promote axonal regrowth across the injured site	1180
@VP	could decrease the inhibitory effect of limiting axonal re-growth after SCI	1364
@VP	decrease the inhibitory effect of limiting axonal re-growth after SCI	1370
@VP	limiting axonal re-growth after SCI	1404
@VP	has been shown to improve following ChABC treatment	1465
@VP	been shown to improve following ChABC treatment	1469
@VP	shown to improve following ChABC treatment	1474
@VP	to improve following ChABC treatment	1480
@VP	improve following ChABC treatment	1483
@VP	to support axon innervations to targets	1596
@VP	support axon innervations to targets	1599
@VP	combining olfactory mucosa progenitor cell -LRB- OMPC -RRB- transplantation	1688
@VP	can promote axonal re-growth across the lesion site	1754
@VP	promote axonal re-growth across the lesion site	1758
@VP	enhance the consistency of stepping in spinally transected rats	1810
@VP	stepping in spinally transected rats	1837
@VP	transplanting into the spinal cord parenchyma	1922
@VP	were found to spread and migrate toward the lesion region of spinal cord	1979
@VP	found to spread and migrate toward the lesion region of spinal cord	1984
@VP	to spread and migrate toward the lesion region of spinal cord	1990
@VP	spread and migrate toward the lesion region of spinal cord	1993
@VP	were consistent and approached that of intact rats	2290
@VP	were consistent	2290
@VP	approached that of intact rats	2310
@VP	restoring the injured spinal cord	2370
@VP	will be further investigated	2404
@VP	be further investigated	2409
@VP	further investigated	2412
@VP	were pre-induced by GDNF	2544
@VP	did through the negative control method	2717
@VP	were differentiated by GDNF-induction for 7 days	2768
@VP	differentiated by GDNF-induction for 7 days	2773
@VP	was used for cellular determination with various antibodies such as NG2 and O4	2844
@VP	used for cellular determination with various antibodies such as NG2 and O4	2848
@VP	expressed NG2 -LRB- a marker of oligodendrocyte progenitor cells -RRB- and O4	2979
@VP	co-localized with O4	3072
@VP	could express NG2	3165
@VP	express NG2	3171
@VP	expressed O4 -LRB- scale bar , 20µm -RRB-	3200
@VP	shows the T8 transection site	3344
@VP	outlined in -LRB- A -RRB-	3424
@VP	BrdU-labeled OMPCs	3446
@VP	is 100µm	3609
@VP	were observed in the spinal cord transection site	3807
@VP	observed in the spinal cord transection site	3812
@VP	did not differentiate into astrocytes , expressing GFAP -LRB- green -RRB-	3874
@VP	differentiate into astrocytes , expressing GFAP -LRB- green -RRB-	3882
@VP	expressing GFAP -LRB- green -RRB-	3913
@VP	was shown in -LRB- G -RRB-	3990
@VP	shown in -LRB- G -RRB-	3994
@VP	were found within the injected region of spinal cord	4027
@VP	found within the injected region of spinal cord	4032
@VP	was a strong expression of GFAP in the lesion	4087
@VP	were not the exogenous grafting cells	4154
@VP	walking	4340
@VP	displayed a recorded graph to be a standard reference gait	4348
@VP	to be a standard reference gait	4375
@VP	be a standard reference gait	4378
@VP	walking gaits of left and right hind limbs	4454
@VP	were individually gauged	4497
@VP	individually gauged	4502
@VP	repairing treatment	4627
@VP	was chaotic	4647
@VP	resembled the normal trajectory	4743
@VP	fail to re-grow	4882
@VP	to re-grow	4887
@VP	re-grow	4890
@VP	have been reported	4971
@VP	been reported	4976
@VP	reported	4981
@VP	was no significant effect on the motor function improvement -LSB- 10 -RSB-	5001
@VP	triggers in the formation of a dense astroglial scar at the lesion site	5124
@VP	is a major component of glial scars in injured spinal cords -LSB- 10,12,13 -RSB-	5237
@VP	sprouting	5468
@VP	were detected by HRP-tracer within the spinal cord lesion area -LSB- 8 -RSB-	5655
@VP	detected by HRP-tracer within the spinal cord lesion area -LSB- 8 -RSB-	5660
@VP	surrounded the regrown axons within the lesion site	6060
@VP	to promote neural regeneration in SCI	6196
@VP	promote neural regeneration in SCI	6199
@VP	guide the sprouting of axons across the lesion site in spinal cord	6349
@VP	promote remyelination around the re-grown axons -LSB- 3,18 -RSB-	6419
@VP	may be a potent therapeutic strategy for SCI	6532
@VP	be a potent therapeutic strategy for SCI	6536
@VP	to generate neurosphere suspension	7012
@VP	generate neurosphere suspension	7015
@VP	were collected	7094
@VP	collected	7099
@VP	incubated them with 0.025 % trypsin -- EDTA in Ca2 + - and Mg2 +	7114
@VP	free solution -LRB- GIBCO , Grand Island , NY -RRB- for 5 min	7172
@VP	re-suspended them to remove dissociated solution	7226
@VP	to remove dissociated solution	7244
@VP	remove dissociated solution	7247
@VP	dissociated solution	7254
@VP	were incubated at 37 ◦ C , with 5 % CO2 in air , for 2 weeks subcultured	7282
@VP	incubated at 37 ◦ C , with 5 % CO2 in air , for 2 weeks subcultured	7287
@VP	subcultured	7339
@VP	were either used for cellular characterization by immunocytochemistry assay	7405
@VP	used for cellular characterization by immunocytochemistry assay	7417
@VP	seeded on the pre-coated poly-l-lysine -LRB- 10µg/ml -RRB- dish	7533
@VP	incubated in our defined differentiation medium	7592
@VP	were added to the DMEM/F12 culture medium -LRB- Invitrogen -RRB-	7686
@VP	added to the DMEM/F12 culture medium -LRB- Invitrogen -RRB-	7691
@VP	were changed every 2 days	7746
@VP	changed every 2 days	7751
@VP	removed the solution to wash the cells twice -LRB- 5 min each time -RRB-	7878
@VP	to wash the cells twice	7899
@VP	wash the cells twice	7902
@VP	were covered by 0.2 % Triton-X 100 -LRB- Sigma , St.	7952
@VP	covered by 0.2 % Triton-X 100 -LRB- Sigma , St.	7957
@VP	was used as a blocking solution at room temperature for 1 h.	8097
@VP	used as a blocking solution at room temperature for 1 h.	8101
@VP	selected five regions in each well	8434
@VP	comparing them with all of the cells from each region	8507
@VP	shown in Fig. 1	8565
@VP	were cultured in 10 ng/ml GDNF-containing medium in vitro	8593
@VP	cultured in 10 ng/ml GDNF-containing medium in vitro	8598
@VP	had a branching neurite , oligodendrocyte progenitor cell-like morphology	8661
@VP	generated extended neurites	8745
@VP	generated oligodendrocyte progenitor cells expressing NG2 -LRB- red -RRB-	8951
@VP	expressing NG2 -LRB- red -RRB-	8994
@VP	overlapped with O4-immunopositive cells -LRB- green -RRB- mostly	9020
@VP	To examine the role of grafted OMPCs in regeneration of SCI rats	9076
@VP	examine the role of grafted OMPCs in regeneration of SCI rats	9079
@VP	incubated for 24 h	9161
@VP	to label the OMPCs before transplantation	9181
@VP	label the OMPCs before transplantation	9184
@VP	BrdU-labeled OMPCs	9228
@VP	using a Hamilton syringe after ChABC delivery	9316
@VP	harvested and immersed in 4 % paraformaldehyde solution for an additional 12 h.	9618
@VP	was performed following the immunochemistry procedure	9720
@VP	performed following the immunochemistry procedure	9724
@VP	was used for primary antibodies	9988
@VP	used for primary antibodies	9992
@VP	were used for peroxidase staining for GAP-43	10071
@VP	used for peroxidase staining for GAP-43	10076
@VP	conjugated to Alexa Flour-488 and 568	10175
@VP	were used to detect other signals such as GFAP , NG2 , and BrdU	10213
@VP	used to detect other signals such as GFAP , NG2 , and BrdU	10218
@VP	to detect other signals such as GFAP , NG2 , and BrdU	10223
@VP	detect other signals such as GFAP , NG2 , and BrdU	10226
@VP	shown in Fig. 2	10295
@VP	were co-localized with NG2	10328
@VP	co-localized with NG2	10333
@VP	in the lesion site -LRB- Fig. 2A -RRB- after 8 weeks of transplantation	10356
@VP	did not continue to differentiate into the fate specific cell lineages	10437
@VP	continue to differentiate into the fate specific cell lineages	10445
@VP	to differentiate into the fate specific cell lineages	10454
@VP	differentiate into the fate specific cell lineages	10457
@VP	drawing higher magnification images from the regions in Fig. 2D	10762
@VP	were observed in the spinal cord transection site	10867
@VP	observed in the spinal cord transection site	10872
@VP	did not differentiate into astrocytes , expressing GFAP -LRB- green -RRB-	10933
@VP	differentiate into astrocytes , expressing GFAP -LRB- green -RRB-	10941
@VP	expressing GFAP -LRB- green -RRB-	10972
@VP	were not observed to proceed to their differentiated courses	11058
@VP	observed to proceed to their differentiated courses	11067
@VP	to proceed to their differentiated courses	11076
@VP	proceed to their differentiated courses	11079
@VP	differentiated courses	11096
@VP	expressing NG2 within the spinal cord lesion region 8 weeks	11198
@VP	was not suitable for the differentiation date for the grafted OMPCs	11369
@VP	guide the sprouting of axons across the spinal cord lesion site	11507
@VP	promote remyelination around the re-grown axons	11574
@VP	did not differentiate into the mature cell lineages in vivo	11912
@VP	differentiate into the mature cell lineages in vivo	11920
@VP	did not fit for the differentiation of grafted OMPCs	12078
@VP	fit for the differentiation of grafted OMPCs	12086
@VP	are involved in nervous system plasticity regulation and in response to injuries	12209
@VP	involved in nervous system plasticity regulation and in response to injuries	12213
@VP	promote axonal regeneration	12343
@VP	replace the destroyed cells within the spinal cord lesion region -LSB- 11 -RSB-	12425
@VP	will be required to investigate in our next study	12595
@VP	be required to investigate in our next study	12600
@VP	required to investigate in our next study	12603
@VP	to investigate in our next study	12612
@VP	investigate in our next study	12615
@VP	was first analyzed by BBB	12685
@VP	analyzed by BBB	12695
@VP	were above scale 4 , which indicates the weight bearing ability	12747
@VP	indicates the weight bearing ability	12773
@VP	reached scale 4 since the third week -LRB- Fig	12860
@VP	-RRB-	12905
@VP	was focused on the combine treatment	12938
@VP	focused on the combine treatment	12942
@VP	combine	12957
@VP	performing all experimental procedures	13850
@VP	were placed on the treadmill to evaluate their walking gait	13961
@VP	placed on the treadmill to evaluate their walking gait	13966
@VP	to evaluate their walking gait	13990
@VP	evaluate their walking gait	13993
@VP	made of heavy cloth	14283
@VP	supported their weight on the moving treadmill belt	14424
@VP	were never stranded in a harness	14541
@VP	stranded in a harness	14552
@VP	started at 7 cm/s and reached a maximum of 21 cm/s for 20 min	14606
@VP	started at 7 cm/s	14606
@VP	reached a maximum of 21 cm/s for 20 min	14628
@VP	were able to step at 20 cm/s for 20 min by the third week of training	14694
@VP	to step at 20 cm/s for 20 min by the third week of training	14704
@VP	step at 20 cm/s for 20 min by the third week of training	14707
@VP	was given to each rat after the bipedal training sessions	14787
@VP	given to each rat after the bipedal training sessions	14791
@VP	were measured for each animal	15001
@VP	measured for each animal	15006
@VP	was defined as the time interval between two successive paw contacts by one limb	15045
@VP	defined as the time interval between two successive paw contacts by one limb	15049
@VP	were typically recorded for each animal	15195
@VP	recorded for each animal	15210
@VP	were used to compute the coupling between the hind limbs -LSB- 5,19,22 -RSB-	15254
@VP	used to compute the coupling between the hind limbs -LSB- 5,19,22 -RSB-	15259
@VP	to compute the coupling between the hind limbs -LSB- 5,19,22 -RSB-	15264
@VP	compute the coupling between the hind limbs -LSB- 5,19,22 -RSB-	15267
@VP	walking patterns of repaired rats -LRB- Fig. 3C -RRB-	15366
@VP	were similar to that of the normal ones -LRB- Fig. 3A -RRB-	15410
@VP	was not strong	15585
@VP	approached the intact rats -LRB- Fig. 3A -RRB-	15693
@VP	dragging	15875
@VP	have been corroborated to examine small changes in hind limb function	15924
@VP	been corroborated to examine small changes in hind limb function	15929
@VP	corroborated to examine small changes in hind limb function	15934
@VP	to examine small changes in hind limb function	15947
@VP	examine small changes in hind limb function	15950
@VP	was used to analyze the difference between treated and untreated SCI rats	16037
@VP	used to analyze the difference between treated and untreated SCI rats	16041
@VP	to analyze the difference between treated and untreated SCI rats	16046
@VP	analyze the difference between treated and untreated SCI rats	16049
@VP	approximated the patterns of intact rats , compared to the untreated group	16200
@VP	did not generate mature cell phenotypes	16304
@VP	generate mature cell phenotypes	16312
@VP	could be found surviving within the spinal cord lesion region	16350
@VP	be found surviving within the spinal cord lesion region	16356
@VP	found surviving within the spinal cord lesion region	16359
@VP	surviving within the spinal cord lesion region	16365
@VP	was confirmed with gait analysis on the treadmill	16443
@VP	confirmed with gait analysis on the treadmill	16447
@VP	associated with immunomodulation of OMPC transplantation	16509
@VP	will be investigated in detail in future	16566
@VP	be investigated in detail in future	16571
@VP	investigated in detail in future	16574
@VP	may be associated with the timing of delivery	16638
@VP	be associated with the timing of delivery	16642
@VP	associated with the timing of delivery	16645
@VP	are up-regulated and accumulate in the lesion site	16714
@VP	up-regulated and accumulate in the lesion site	16718
@VP	up-regulated	16718
@VP	accumulate in the lesion site	16735
@VP	promote sprouting in injured spinal cord	16861
@VP	sprouting in injured spinal cord	16869
@VP	improve fractional motor functions -LSB- 8 -RSB-	16906
@VP	can alter the outcome of macrophage attack	16987
@VP	alter the outcome of macrophage attack	16991
@VP	preventing macrophage-induced retraction of axons -LSB- 2 -RSB-	17127
@VP	limit the effect of ChABC in vivo.ChABCis thermally sensitive	17367
@VP	is lost within 3 -- 5 days at 37 ◦ C -LSB- 20 -RSB-	17463
@VP	lost within 3 -- 5 days at 37 ◦ C -LSB- 20 -RSB-	17466
@VP	would be needed at the least 2 -- 3 days -LSB- 20 -RSB-	17572
@VP	be needed at the least 2 -- 3 days -LSB- 20 -RSB-	17578
@VP	needed at the least 2 -- 3 days -LSB- 20 -RSB-	17581
@VP	to create clinically viable delivery methods for the spatially	17644
@VP	create clinically viable delivery methods for the spatially	17647
@VP	reconstituting the injured spinal cord	17934
@VP	have been demonstrated to replace damaged cell types	17973
@VP	been demonstrated to replace damaged cell types	17978
@VP	demonstrated to replace damaged cell types	17983
@VP	to replace damaged cell types	17996
@VP	replace damaged cell types	17999
@VP	is not the only one role for cellular replacement in SCI	18098
@VP	have also been shown to express immunomodulatory properties -LSB- 16,21 -RSB-	18381
@VP	been shown to express immunomodulatory properties -LSB- 16,21 -RSB-	18391
@VP	shown to express immunomodulatory properties -LSB- 16,21 -RSB-	18396
@VP	to express immunomodulatory properties -LSB- 16,21 -RSB-	18402
@VP	express immunomodulatory properties -LSB- 16,21 -RSB-	18405
@VP	enhance axonal elongation and promote functional recovery	18516
@VP	enhance axonal elongation	18516
@VP	promote functional recovery	18546
@VP	must be investigated	18753
@VP	be investigated	18758
@VP	investigated	18761
@VP	reported that progenitor cells could produce growth factors	18795
@VP	could produce growth factors	18826
@VP	produce growth factors	18832
@VP	differentiated factors , and neurotrophic factors	18856
@VP	to regulate neurogenesis and synaptic plasticity during their development	18905
@VP	regulate neurogenesis and synaptic plasticity during their development	18908
@VP	designing quantitative techniques to assess motor function after treatment	18999
@VP	to assess motor function after treatment	19033
@VP	assess motor function after treatment	19036
@VP	to support body weight	19171
@VP	support body weight	19174
@VP	be evaluated with Basso , Beattie , and Bresnahan -LRB- BBB -RRB- scale analysis	19204
@VP	evaluated with Basso , Beattie , and Bresnahan -LRB- BBB -RRB- scale analysis	19207
